



a requirement for the development
of dendrimer-based
pharmaceuticals
Daniel Q. McNerny,1∗ Pascale R. Leroueil2 and James R. Baker3
Dendrimer conjugates for pharmaceutical development are capable of enhancing
the local delivery of cytotoxic drugs. The ability to conjugate different targeting
ligands to the dendrimer allows for the cytotoxic drug to be focused at the intended
target cell while minimizing collateral damage in normal cells. Dendrimers
offer several advantages over other polymer conjugates by creating a better
defined, more monodisperse therapeutic scaffold. Toxicity from the dendrimer,
targeted and nonspecific, is not only dependent upon the number of targeting and
therapeutic ligands conjugated, but can be influenced by the repeating building
blocks that grow the dendrimer, the dendrimer generation, as well as the surface
termination.  2010 John Wiley & Sons, Inc. WIREs Nanomed Nanobiotechnol 2010 2 249–259
The narrow therapeutic index of many cytotoxictherapeutics, including doxorubicin, vincristine,
cyclophophamide, and paclitaxel, often limits their
effectiveness as they must be delivered in suboptimal
dosages to prevent side effects in the patient.1 To
remedy this problem, targeted scaffolds can be used to
deliver the drug the desired location in an increased,
local concentration. As a result, the drug is effective
only where it is needed and the undesired side
toxicities are diminished. Examples of drug-targeting
systems include nanoparticles, liposomes, micelles,
linear polymers, branched polymers, and dendrimers.2
Dendrimer-based platforms have achieved atten-
tion for use in pharmaceutical applications.3–13 Sim-
ilar to other polymeric carriers, dendrimers can be
synthesized to avoid structural toxicity and immuno-
genicity. However, the unique branched structure of
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the dendrimer allows for the platform to overcome
several significant challenges faced in the develop-
ment of other polymeric carriers. Many polymers are
highly heterogeneous, making characterization and
batch reproducibility inherently difficult. Therapeu-
tics with multiple drug or imaging moieties conjugated
to a carry are heterogeneous populations that become
more disperse as more functionalities are added. These
problems often lead to unintended variations in bio-
logical activity, because the structural platform is
not well understood and is difficult to reproduce.
In contrast, the controlled synthesis and growth of
dendrimers results in exceptionally low degrees of
dispersity [polydispersity index (PDI) <1.1]14,15 with
well-defined numbers of terminal groups for the conju-
gation of functional molecules, allowing for improved
reproducibility. The dendrimer’s ability to mimic the
size, solubility, and shape of human proteins makes
the technology an ideal choice for many therapeutic
and diagnostic applications. Being 1–10 nanometers
in size enables dendrimers to efficiently diffuse across
the vascular endothelium, internalize into cells, and
be rapid cleared by the kidneys.16,17 This helps to
avoid long-term toxicities and reduces the need for a
rapidly degradable platform. The availability of mul-
tiple reactive surface groups enables the dendrimer
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to carry a higher payload of functional molecules,
enhancing targeted toxicity.
Dendrimers have been produced or are under
commercial development for several biomedical appli-
cations. A topical, polylysine dendrimer-based micro-
bicide, VivaGel, is being developed by Starpharma
for the prevention of HIV transmission and other sex-
ually transmitted diseases. SuperFect is a dendrimer-
based material used for gene transfection. Den-
drimers have also been developed as diagnostic tools.
Gadomer-17, a polylysine dendrimer functionalized
with gadolinium chelates, was under development
as a magnetic resonance imaging (MRI) contrast
agent. Stratus CS acts as a biosensor for car-
diac markers in an effort to rapidly diagnosis heart
attacks.
In recognition of these varied structures and
applications, one must be careful not to generalize
dendrimer biological activity and toxicity. The
biocompatibility, solubility, and other characteristics
of dendrimers are all highly dependent upon the
chemical backbone of the dendrimer as well as the
surface termination. These structural considerations
must be evaluated when determining if a particular
dendrimer is safe for pharmaceutical use. This review
will detail the factors contributing to dendrimer
biocompatibility and define any trends associated
with structure. We will first briefly discuss dendrimer
chemistry and outline which chemical backbones have
been successfully used for biological applications.
We will then detail targeted delivery of dendrimer
scaffolds, which allows for enhanced specific toxicity.
This will involve a discussion of the mechanisms
involved in targeting as well as the mechanisms
involved in the biological confirmation of the activity.
Finally, we will address nonspecific toxicities related
to dendrimer platforms and the means to minimize
these effects.
DENDRIMER CHEMISTRY
Dendrimers are defined by their core-shell structure
(Figure 1), where the dendrimer approximately dou-
bles in size and number of functional surface groups
with each additional shell (or generation) added
to the core. Shells are synthesized by alternating
monomer reactions by means reviewed extensively
elsewhere.12,18 Specialized dendrimer backbones can
be synthesized by varying the monomer units. The
biological properties of the dendrimer are largely
influenced by the chemical backbone and surface
termination.
For a dendrimer to be an appropriate vehicle for
drug delivery in vivo, they must be nontoxic, nonim-
munogenic, and be capable of targeting and reaching










































FIGURE 1 | The core-shell architecture of a
poly(amidoamine) (PAMAM) dendrimer with an
ethylene diamine core with a typical generation
numbering scheme. Half-generation PAMAM
dendrimers may have carboxyl or methyl ester
terminal groups. Unmodified full-generation
PAMAM dendrimers have amine surface groups.
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FIGURE 2 | Absolute size comparison of PAMAM dendrimers of
varied generation to several key proteins. (Reprinted with permission
from Ref 31. Copyright 2007 American Chemical Society).
while being stable enough to remain in circulation.
The vast majority of the dendrimers synthesized and
published in literature are insoluble in physiological
conditions or are incapable of remaining soluble after
the addition of functional molecules and are inappro-
priate for biological applications. However, several
classes of dendrimers have been shown to be use-
ful scaffolds for biomedical applications; examples
include polyesters,19,20 polylysine,21, and polypropy-
leneimine (PPI or DAB) dendrimers.22,23
The most widely used dendrimers in biomedical
applications are poly(amidoamine) (PAMAM) den-
drimers. The polyamide backbone synthesized from
repeating reactions of methyl acrylate and ethylene-
diamine helps the macromolecule maintain water
solubility and minimizes immunogenicity.24 PAMAM
dendrimers of different generation also are able
to mimic the size and properties of globular pro-
teins readily found in the body (Figure 2). However,
PAMAM dendrimers offer several advantages over
proteins, as proteins are fragile and can more easily
denature because of changes in temperature, light,
or pH.15 The amine-terminated surface of full gener-
ation PAMAM dendrimers allows for easy surface
modification, enabling the platform to carry and
solubilize hydrophobic therapeutic molecules, such
as methotrexate,16,24–27 in physiological conditions.
PAMAM dendrimers exhibit little nonspecific toxicity
if the surface amines have been neutralized or appro-
priately modified.10,12,28–31
Additional dendrimers have been synthesized
to be biodegradeable by incorporating peptide-based
backbones that act as substrates for metabolic
pathways.32 Although these constructs could greatly
enhance the prevention of bioaccumulation, they also
serve as a reminder to consider potential degradation
products of the dendrimer platforms, as they may
exhibit an undesired toxicity.
TARGETED TOXICITY
Targeted delivery of cytotoxic drugs aims to eliminate
nonspecific toxicities while increasing local concen-
trations in specific materials through a number of
mechanisms.33 Similar to other polymeric materials,
dendrimers can target and achieve enhanced specificity
via active and passive pathways.
Surface Decoration and Functionalization
Active targeting uses a molecule, such as an antibody
or ligand, to mediate delivery of its payload (drug
or otherwise) to cells by binding to cell-specific
molecules. Typically, these molecules or delivery
vehicles bind through receptors highly expressed on
target cells. The interactions between the targeting
ligand and cell-surface receptor allow the therapeutic
or payload to selectively reach the cancer cells
and even be ushered inside via receptor-mediated
processes.1
The multivalent effect associated with the dis-
play of multiple binding ligands on the dendrimer
surface enhances the uptake of the dendritic scaffold
compared to single ligands.14 Multivalent interac-
tions, caused by the simultaneous binding of multiple
ligands, allow for the dendrimers to increase the bind-
ing avidities of the platform, even when individual
ligands have low affinities for the targeted recep-
tor receptor. The PAMAM platform (Figure 3) has
been successfully used as a scaffold for the attach-
ment of multivalent targeting molecules including
antibodies,34–38 peptides,39,40 T-antigens,41–43, and
folic acid.16,24,25,44–50 The targeting ligands anchor
the dendrimers to locations where specific recep-
tors are expressed on cell surfaces. Hong showed
the avidity effects of dendrimers with an increas-
ing amount of conjugated folic acid.14 The surface
plasmon resonance data showed a linear increase in
on-rate and exponential decrease in off-rate of the
targeted dendrimer for increasing amount of folic acid
per dendrimer. The increased avidity allows targeted
dendrimer-drug conjugates to deliver a higher dose
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FIGURE 3 | Schematic of a multifunctional targeted nanodevice
based on the PAMAM dendrimer scaffold. (Reprinted with permission
from Ref 31. Copyright 2007 American Chemical Society).
specifically to targeted cells while avoiding normal
cells, thus avoiding the systemic toxicity of current
therapeutics.
In 2002, a Quintana et al.51 demonstrated
mediated internalization of folic acid functionalized
G5 PAMAM dendrimers by folate receptors on
carcinoma KB cells. This study demonstrated a
100-fold improvement in cytotoxicity of targeted
dendrimers with methotrexate compared to free
methotrexate. In 2004, Thomas et al.36 demonstrated
successful targeting of prostate specific membrane
antigens by antibody-conjugated dendrimers. The
following year, a second study by Thomas et al.46
demonstrated internalization of a folic acid targeted
dendrimers carrying methotrexate. Results from this
study indicated internalization was through folic
acid receptor-mediated endocytosis, suggesting that
the delivery devices might be able to overcome
methotrexate induced drug resistance.
Kukowska-Latallo et al.16 demonstrated the
effectiveness of the multifunctional folic acid,
methotrexate-conjugated dendrimer in vivo. Con-
ducted in SCID mice bearing KB tumors for 99 days,
biweekly injections of the multifunctional dendrimer
delivery device caused a significant increase in
the survival rate compared to treatment with free
methotrexate. The conjugate showed 10-fold higher
efficacy compared to the equivalent dose of free drug
(Figure 4).
Although dendrimers generally offer an
increased synthetic control and monodispersity over
other polymeric platforms, understanding conjugate
product distributions is still a critical area of interest
shared over all multivalent or multifunctional
materials. Functionalized dendrimers are typically
reported to have an average number of targeting
ligands or therapeutics, where the distribution of
the population cannot be distinguished by most
common characterization techniques including NMR,
GPC, and MALDI.24 The distributions become
increasingly complicated as additional functionalities
are conjugated to the dendrimer, though it should
be noted that the polydispersity of these multifunc-
tional dendrimers remain lower than other common
polymeric platforms. Minute changes in reaction
conditions between batches can significantly alter
these distributions and as a result affect the biological
activity, including toxicity, of the material. It is possi-
ble synthetic errors or alterations can create portions
of the product distribution that are nonactive or,
worse, nonspecifically toxic. Because of this, it would
be highly desirable if structure-function studies could
be performed on the individual populations within
the distribution to determine which populations have
the desirable biological activities. Unfortunately, no
protocol for separating these populations has been
published. New developments in dendrimer synthesis
aim to bypass issues of distributions completely
through orthogonal coupling chemistry.52 One might
imagine that future dendritic platforms having
enhanced monodispersity with an optimal number
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FIGURE 4 | Tumor growth in severely combined immunodeficient
(SCID) mice bearing KB xenografts during treatment with
tri-functional G5 dendrimer with folic acid (FA), fluorescein (FI), and
methotrexate (MTX). The dose of the conjugate (55.0 mg/kg) was
equivalent to the lowest dose of free methotrexate (5.0 mg/kg) is as
effective in tumor growth delay as the intermediated dose of free
methotrexate (21.7 mg/kg).16
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application. Regardless, until dendrimers with exact
numbers of ligands be separated or synthesized, the
distribution of the ligands between batches must
be consistent. Otherwise, it will be difficult for
dendrimers to be a viable option for many therapeutic
applications.
Enhanced Permeation and Retention Effect
In addition to ligand/receptor targeting, dendrimers
have also been reported to use passive approaches
that exploit the size relationship between large
macromolecules and the pore size in tumor tissue.
This is called the enhanced permeation and retention
effect (EPR) and is often seen in cancerous tissues
as compared with healthy cells.53–55 The defective
architecture and decreased lymphatic drainage present
in tumor tissues result in the macromolecular complex
to be retained within the tumor. This is usually a
less effective approach particularly in smaller tumors
where the vasculature is not ‘leaky’. Malik successfully
showed that PAMAM dendrimers conjugated with
the hydrophobic anticancer drug, cisplatin, selectively
accumulated in B16F10 tumor-bearing mice in 50-
fold greater quantities compared to free drug.56
Decreased systemic toxicity and increased solubility
were reported for the conjugated cisplatin. Bhadra
used PEGylated G4 PAMAM dendrimers for carriers
of anticancer drug 5-fluorouracil.57 The platforms
were injected intravenously into the caudal vein of
rats and the blood level of drug was measured. The
drug level of 5-fluorouracil in PEGylated samples was
enhanced, and detectable up to 12 h after the drug
was injected.
Enhanced retention of dendrimers has also
been shown in inflamed tissues. Chauhan complexed
the anti-inflammatory drug indomethacin to G4
PAMAMs and injected intravenously to arthritic
rats.58 The indomethacin concentrations in inflamed
joints were 2.29 times greater in complexed dendrimer
treated animals compared to animals treated with free
drug. The arthritic joint contained lymphatic drainage,
but the complex still had an extended retention at
the inflamed site. Asthana reported similar results in
vitro and in vivo in inflammatory models with anti-
inflammatory drug flurbiprofen/PAMAM dendrimer
formulations.59
Minimizing Nonspecific Toxicities
In addition to enhancing desired specific toxicities of
dendrimer platforms for applications such as cancer
therapy, it is crucial to understand and minimize non-
specific interactions with healthy cells. The dendrimer
periphery can significantly alter the cytotoxicity of
the platform. Similar to other polymeric materi-
als, cationic dendrimer surface charges interact with
negatively charged biological surface to lead to struc-
tural disruptions.60 Modification of the dendrimer
can minimize these effects. Larger generation den-
drimers typically display a smaller influence from their
well-protected cores as charges on their arms can be
shielded by backfolding and steric effects.
In general, cationic dendrimers have been shown
to exhibit nonspecific toxicities (Figure 5) and must
be modified to prevent accumulation in the liver.61,62
Roberts showed that cationic PAMAM dendrimers
were toxic at low concentrations in V79 Chinese ham-
ster lung fibroblasts.63 Ninety percent cell death was
observed using MTT assays at 1 nM for generation
3, 10 µM for generation 5, and 100 nM for gener-
ation 7. The same group observed similar toxicities
for cationic PAMAM, DAB, and diaminoethane den-
drimers in B16F10 murine melanoma, corticotropin-
releasing factor (CRF) human lymphoblastic leukemia
and HepG2 human hepatoma.61 Cationic PAMAM
dendrimers were less toxic than DAB dendrimers of
equal surface charge.
PAMAM dendrimers with increasing charge
densities have shown increasing toxicities in Caco-2
cells.62 It was shown that the cytotoxicity of amine-
terminated dendrimers was significantly higher when
compared to anionic half-generation dendrimers at
concentrations across the micromolar range. The
cytotoxicity of each type of dendrimer increased with
size and concentration. Cytoxicity was significantly
decreased (IC50 approximately 0.13 mM to greater
than 1 mM) when the cationic dendrimer surface was
modified with six lauroyl or four PEG chains, which
likely shielded the positive charge of the surface.
Quintana in 200251 and Nigavekar in 200464
showed that by neutralizing the surface amines of
PAMAM dendrimers with acetyl groups, nonspecific
toxicities and uptake could be minimized. The acetyl
capping of the dendrimer also allows for increased
clearance from the body, minimizing effects from long-
term treatment. Further evidence that PEGlyation
of amino-terminated PAMAM dendrimers reduces
immunogenicity and increases solubility was shown
by Kobayashi.65 The PEG terminated dendrimer
increased the lifetime in the blood stream compared to
the cationic parent material. Hydroxyl and methyoxyl
terminated polyester dendrimers were also shown to
be nontoxic in vivo up at high concentrations up to
40 mg/kg.19,66 The differences in toxicities between
cationic and anionic dendrimers have also been
confirmed in vivo.67 Using a zebrafish embryo model,
carboxyl terminated dendrimer was significantly less
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(a)  Control (b)  PAMAM gen 4; 10 µg/mL
(c)  PAMAM gen 4; 1 mg/mL (d)  PAMAM gen 3.5; 1 mg/mL
FIGURE 5 | Scanning electron
microscopy of red blood cell (RBC)
incubated with poly(amidoamine)
(PAMAM) dendrimers for 1 h. The
cationic dendrimer (generation 4)
disrupts the structure the integrity of
the cell structure at low
concentrations. (Reprinted with
permission from Ref 61. Copyright
2000 Elsevier).
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FIGURE 6 | Effect of net charge on amine-terminated G4 and
carboxylic acid-terminated G3.5 dendrimer-induced mortality in the
zebrafish embryo. (A) Mortality assessed at 120 h post-fertilization for
embryos exposed to G4 or RGD-G4 dendrimers from 6 to 120 h
post-fertilization. (B) Mortality evaluated at 120 h post-fertilization for
embryos exposed to G3.5 or RGD-G3.5 dendrimers from 6 to 120 h
post-fertilization. (Reprinted with permission from Ref 67. Copyright
2007 Elsevier).
toxic than G4 amine-terminated dendrimer (Figure 6).
In the same study, surface modification with RGD also
reduced toxicity.
The mechanism behind nonspecific binding of
cationic dendrimers has been explored by Hong
and Leroueil.29,30,60 They have shown that positively
charged polymeric material, including amine termi-
nated PAMAM dendrimers, causes the formation of
holes in cell membranes resulting in nonspecific inter-
nalization of material (Figure 7). Studies were per-
formed on dimyristoylphosphatidylcholine (DMPC)
lipid bilayers atomic force microscopy and on KB
and Rat2 cells in culture, and this was evaluated
by LDH release assays. Generation 7 PAMAM den-
drimers were observed to form holes (15–40 nm in
diameter) in DMPC while generation 5 dendrimers
expended existing holes. Experimental results suggest
that the dendrimer is also more efficient at increasing
membrane permeability compared to a linear polymer
of the same charge density. Neither hole formation
nor internalization was observed for charge neutral,
nontargeted dendrimers.
Further understanding the toxicity of cationic
dendrimers is crucial for successful use in gene trans-
fection applications,8,68–71 where a positively charged
surface is required for ionic complexation with DNA
and to act as a proton buffer, leading to endo-
some disruption.71 Although dendrimer polyplexes
have shown effective transfection and lower toxicities
254  2010 John Wiley & Sons, Inc. Volume 2, May/June 2010
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FIGURE 7 | Poly(amidoamine) (PAMAM) dendrimer interactions with biological membranes. (I) Atomic force microscopy (AFM) observation of
dimyristoylphosphatidylcholine (DMPC) supported lipid bilayers (a), (c), and (e) before and after incubation with (b) amine-terminated G7 (G7-NH2),
(d) amine-terminated G5 (G5-NH2), and (f) acetylated G5 (G5-Ac) PAMAM dendrimers, respectively. (II) Space-filling models of chemical structures of
(a) G7-NH2, (b) G5-NH2, and (c) G5-Ac PAMAM dendrimers. (III) Lactate dehydrogenase (LDH) leakage as a result of cell exposure to PAMAM
dendrimers. (a) Size effect of G7-NH2 and G5-NH2 on the LDH leakage out of KB and Rat2 cells after incubation at 37
◦C for 3 h and (b) surface group
dependency on the LDH leakage at different temperatures. Note that larger dendrimers (G7-NH2) induce formation of new nanoscale holes in the
bilayers as seen in the AFM images and cause more amount of LDH leakage out of live cells than G5-NH2. G5-NH2 dendrimers do not cause new hole
formation in the lipid bilayers but instead expand preexisting defects. In contrast, G5-Ac dendrimers do not cause hole formation, expansion of
preexisting defects, or LDH leakage out of live cells. (Reprinted with permission from Ref 31. Copyright 2007 American Chemical Society).
compared to other polymeric transfection agents in
vitro, further work optimizing toxicity levels must
be performed to translate these devices to clinical
situations.
In addition to serving as a delivery platform,
neutralized or modified dendrimers are being explored
as stable, biocompatible, water-soluble coating for
other devices. Acetylated G5 PAMAM dendrimers
have been attached to carbon nanotubes72 for targeted
delivery and to iron oxide nanoparticles50 for MRI.
These show that the use of dendrimers can be
expanded to enhance the biomedical applicability of
other platforms as well.
Biodistribution
Multiple studies have been performed evaluat-
ing the biodistribution of dendrimers using 125I-
radiolabeling,61,73 gadolinium labeling,74 3H64 or
14C labeling.63 Similar to the effects surface mod-
ifications can have on the toxicity, these labeling
techniques may alter the distribution of the platform.
However, general conclusions as to the fate of
administered dendrimer can be made. Charged and
hydrophobic dendrimers are rapidly cleared from the
circulation, typically by the liver. Hydrophilic den-
drimers with hydroxyl or PEG surfaces have extended
circulation lifetimes. Larger dendrimers delay renal
elimination compared to smaller platforms. Nigavekar
showed that net surface charge of generation 5
PAMAM dendrimers modifies the biodistribution.64
Amine terminated PAMAMs deposition into tissues
is higher than acetylated dendrimers, though the dis-
tribution is similar. Highest levels were found in the
lungs, liver, and kidney. Approximately 50% of the
acetyl capped PAMAMs and approximately 30% of
the amine-terminated PAMAMs were excreted via
urine over 7 days, approximately 25% and approxi-
mately 8% during the first day, respectively.
The biodistribution of targeted systems has
also been studied. In folic acid targeted PAMAMs,
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Kukowska-Latallo et al. showed that levels of the
radiolabeled conjugate increased in tissues expressing
high levels of the folate receptor, the liver, kidney
and tumor, compared with nontargeted dendrimer.16
The nontargeted dendrimer dropped in concentration
significantly 2 h after injection in these tissues. The dif-
ferences in accumulation, distribution, and excretion
supported the preferential uptake model based on folic
acid receptor levels present on the cell membranes.
Yang et al. evaluated the distribution epidermal
growth factor (EGF) targeting boronated PAMAM
dendrimers.75 Rats bearing F98EGFR gliomas and
F98WT (wild-type) receptor negative tumors were used
in the study. Twenty-four hours after administration,
47.4% of the dendrimer dose was located in the
receptor positive gliomas compared with 12.3% in
the wild-type tumor. The mean survival time of rats
receiving the conjugate was 53 days, and only 31 days
for the control.
Although enhanced uptake in target cells has
clearly been demonstrated, the relative accumulation
of targeted dendrimers in target tissue versus healthy
tissue must be taken into account. The use of cell
markers that are expressed in both target and healthy
tissue as targets can lead to potentially toxic accumu-
lations of drug or dendrimer within the healthy tissue.
Although in some cases this risk may be acceptable,
extensive studies must be completed documenting that
the targeted treatment is more effective than systemic
or no treatment. With future developments and as
more cell-specific markers are found, the risks of
harming healthy tissue with targeted dendrimers will
diminish.
CONCLUSION
Dendrimers have been used for multiple targeting,
imaging, and delivery applications. These highly cus-
tomizable devices can be engineered to display an
appropriate amount of specificity through interactions
between conjugated ligands and cellular receptors and
enhanced retention in abnormal tissue architecture,
while minimizing nonspecific uptake and toxicities by
neutralizing surfaces charges. Considerations includ-
ing solubility of the platform, coupling chemistry
required, and required number of ligands needed must
be evaluated when determining the necessary chemical
backbone and generation of dendrimer. Dendrimers
can enhance the toxicity of a material by increasing
the local concentration of a therapeutic via multi-
valent interactions with surface-bound ligands and
by enhancing retention within the targeted tissue.
Nonspecific toxicities have been shown for positively
charged dendrimers, so care must be shown to appro-
priately neutralize the dendritic device.
It has been shown that certain dendrimers, such
as those with the PAMAM backbone and neutralized
surfaces groups, are appropriate for many biological
applications. PAMAM dendrimers expressing various
targeting groups have successfully been used to target
therapeutic and sensing molecules while maintaining
an appropriate level of biocompatibility. The multi-
functional PAMAM dendrimer conjugated with folic
acid and methotrexate will soon enter phase I trials.
For the platform to reach further into the main-
stream, progress must be made in the synthesis and
characterization of the dendrimer platform and its
conjugates. Recent work showing the ability to bet-
ter understand and isolate product distributions in
dendrimer conjugates has the potential to facilitate
an increased awareness of the impact these materials
have on biological systems. By optimizing the product
distribution, the dendrimer platform can offer an even
greater degree of control and customization over other
polymeric delivery devices.
There remains a need to perform appropriate
toxicology studies for dendrimer therapeutics. The
properties of functionalized or modified dendrimer
can be significantly different from the parent den-
drimer. It would be inappropriate to draw conclusions
on the toxicity of a functionalized dendrimer based on
the general properties of the scaffold. Effective den-
drimer platforms will succeed in clinical trials only
after specific toxicity testing has been performed on
appropriate animal models. Computer-aided design
can successfully create a biocompatible dendrimer
structures that exploit the advantages of the platform.
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